Atara Biotherapeutics, Inc.

Atara Biotherapeutics is a T-cell immunotherapy company focused on developing allogeneic Epstein-Barr virus (EBV) T-cell platform therapies for cancer and autoimmune diseases. The company's lead product, tab-cel (tabelecleucel), has received marketing authorization as Ebvallo in the European Economic Area (EEA), the United Kingdom (UK), and Switzerland ¹. Tab-cel is also in Phase 3 development in the U.S. for patients with EBV-associated post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, and for other EBV-driven diseases ¹. The company's off-the-shelf, allogeneic T-cell platform allows for rapid delivery of therapy manufactured in advance and stored in inventory, providing treatment for numerous patients, which contrasts with autologous treatments that require patient-specific cell modification ¹.

While there are currently no FDA-approved products for relapsed and/or refractory EBV+ PTLD, and Ebvallo is the only EC-approved product for this indication, some marketed products like rituximab and combination chemotherapy regimens are used off-label ¹. The company estimates several hundred EBV+ PTLD patients in the U.S. in 2019 failed rituximab or rituximab plus chemotherapy ¹. Tab-cel has received Breakthrough Therapy Designation (BTD) from the U.S. FDA for EBV+ PTLD after HCT who have failed rituximab, and orphan designation in the U.S. and EU for EBV+ PTLD following HCT or SOT ¹. In clinical studies, tab-cel monotherapy showed two-year overall survival of approximately 83% in EBV+ PTLD after HCT patients who failed rituximab, and approximately 86% in EBV+ PTLD after SOT patients who failed rituximab ¹. An objective response rate (ORR) of greater than or equal to 50% was observed in these studies ¹.

The core business model revolves around the development and out-licensing of T-cell immunotherapies. The company generates revenue primarily through upfront license fees, milestone payments, and royalties from commercialization agreements, such as the one with Pierre Fabre ¹. The company has also engaged in the sale of future royalty and milestone interests, as seen with the HCRx Agreement ¹. Primary customer segments, once products are approved, would be patients with specific cancers and autoimmune diseases, with commercialization handled by partners like Pierre Fabre ¹.

Tab-cel (Ebvallo) is the company's most advanced product, approved in the EEA, UK, and Switzerland for EBV+ PTLD ¹. It is also in Phase 3 development in the U.S. for the same indication and in Phase 2 for other EBV+ diseases ¹. The company partnered with Pierre Fabre for worldwide commercialization, including an upfront cash payment of $45.0 million in Q4 2021, an additional $30.0 million milestone payment in September 2022, and further upfront cash payments of $20.0 million in January 2024, $20.0 million in April 2024, and $20.0 million in August 2024 for expanded exclusive license grants and regulatory milestones ¹. In December 2025, the milestone payment due upon BLA approval of tab-cel was reduced to $31.0 million in exchange for a potential additional $15.0 million commercial milestone payment ¹. The company is eligible for up to $308.0 million in remaining milestone payments for the Initial Territory and up to $556.0 million for the Additional Territory, plus significant double-digit tiered royalties on net sales ¹.

The company's pipeline previously included ATA3219, an allogeneic CAR T targeting CD19 for B-cell malignancies and autoimmune diseases, and ATA3431, an allogeneic dual CAR T targeting CD19 and CD20 for B-cell malignancies ¹. However, in March 2025, the company announced the decision to pause development of allogeneic CAR T cell programs and discontinue all CAR T operations for ATA3219 and ATA3431, including terminating clinical trials for ATA3219 ¹. The company also stopped development on ATA188 for multiple sclerosis (MS) and a potential next-generation EBV vaccine, returning rights to QIMR Berghofer in May 2025 ¹.

For the fiscal year ended December 31, 2025, the company reported commercialization revenue of $120.772 million ², compared to $128.940 million in 2024 ³. Cost of commercialization revenue was $21.212 million in 2025 ⁴, versus $21.009 million in 2024 ⁵. Total research and development expenses decreased to $37.445 million in 2025 ⁶ from $151.483 million in 2024 ⁷. General and administrative expenses were $26.253 million in 2025 ⁸, down from $39.886 million in 2024 ⁹. The company reported a net income of $32.7 million in 2025 ¹⁰, a significant improvement from a net loss of $(85.4) million in 2024 ¹¹. Interest income was $0.683 million in 2025 ¹², compared to $2.110 million in 2024 ¹³, while interest expense decreased to $3.792 million in 2025 ¹⁴ from $4.615 million in 2024 ¹⁵. As of December 31, 2025, cash and cash equivalents totaled $8.482 million ¹⁶, with no short-term investments ¹⁷, down from $25.030 million in cash and cash equivalents and $17.466 million in short-term investments in 2024 ¹⁸. The accumulated deficit as of December 31, 2025, was $2.0 billion ¹⁹.

The decrease in commercialization revenue in 2025 was primarily due to a year-over-year reduction in revenue from transition activities after tab-cel manufacturing and clinical activities transitioned to Pierre Fabre in March and July 2025, respectively ¹. This decrease was partially offset by an increase in revenue from the sale of inventory to Pierre Fabre and higher deferred revenue recognized in 2025 following the manufacturing transition ¹. Research and development expenses saw a substantial decrease of $114.038 million ²⁰, primarily due to the transition of tab-cel manufacturing activities to Pierre Fabre, reduced headcount from multiple reductions in force, and the pause of CAR T programs ¹. General and administrative expenses also decreased by $13.633 million ²¹ due to reduced headcount ¹. Interest income decreased due to lower cash, cash equivalents, and available-for-sale securities balances ¹.

Significant operational developments in 2025 included multiple reductions in force: approximately 50% in January, 50% in March, 30% in May, and 30% in October, retaining approximately 15 employees ¹. Total severance and related benefits recognized were approximately $7.2 million for the January reduction, $2.8 million for March, $1.4 million for May, and an expected $1.2 million for October ¹. The company completed the transfer of all manufacturing responsibility for tab-cel to Pierre Fabre in March 2025, including the assignment of the Fujifilm MSA and CMO agreements ¹. In July 2025, all clinical and development responsibility for tab-cel was transferred to Pierre Fabre, followed by the transfer of all regulatory activities, including BLA sponsorship, in October 2025 ¹. The FDA issued a Complete Response Letter for the tab-cel BLA in January 2025, citing observations at a third-party manufacturing facility, which led to a clinical hold on IND applications for tab-cel and ATA3219 ¹. The FDA lifted the clinical hold in May 2025 after issues were addressed, and the BLA was resubmitted in July 2025 ¹. However, in January 2026, a second Complete Response Letter was issued, stating the ALLELE trial was no longer considered adequate to support the BLA due to deficiencies in study design, conduct, and analysis ¹.

The company anticipates providing a regulatory update in the second quarter of 2026 regarding the second Complete Response Letter for the tab-cel BLA ¹. This update will follow a Type A meeting requested by Pierre Fabre with the FDA to address the concerns raised ¹.

A major growth area for the company is the potential U.S. approval and commercialization of tab-cel for EBV+ PTLD. Pierre Fabre is now responsible for all regulatory activities, including sponsorship of the tab-cel BLA, and is to use commercially reasonable efforts to obtain BLA approval as soon as possible ¹. Upon BLA approval, the company is entitled to receive a milestone payment of $31.0 million, with an additional $15.0 million potential milestone payment upon achieving a certain commercial milestone ¹. The company is also eligible for significant double-digit tiered royalties as a percentage of net sales of tab-cel (Ebvallo) in the Territory until the later of 12 years after the first commercial sale in each country, the expiration of specified patent rights, or the expiration of all regulatory exclusivity ¹.

Another growth vector is the commercialization of Ebvallo in the Additional Territory by Pierre Fabre. The company is entitled to receive an aggregate of up to $556.0 million in additional potential milestone payments upon achieving certain regulatory and commercial milestones relating to tab-cel in the Additional Territory ¹. Pierre Fabre is responsible, at its cost, for obtaining and maintaining all required regulatory approvals and for commercialization and distribution of tab-cel in the Additional Territory, including conducting any other clinical study required ¹.

Regarding margin trajectory and cost structure, the company has undertaken significant workforce reductions in 2025, including approximately 50% in January, 50% in March, 30% in May, and 30% in October, retaining approximately 15 employees ¹. These reductions reflect a prioritization around key research and development programs and a reduction of the expense profile ¹. The company recognized approximately $7.2 million in severance and related benefits for the January reduction, $2.8 million for March, $1.4 million for May, and expects approximately $1.2 million for the October reduction ¹. The majority of these costs are cash expenditures and primarily represent one-time termination benefits ¹.

In terms of supply chain and manufacturing, all manufacturing responsibility for tab-cel was transferred to Pierre Fabre in March 2025, with Pierre Fabre now responsible for manufacturing and supplying tabelecleucel for development and commercialization worldwide at its cost ¹. Pierre Fabre also assumed costs related to remediation of the third-party manufacturing facility to address FDA requests for BLA resubmission ¹. All clinical and development responsibility, including sponsorship of the ALLELE and tab-cel multi-cohort studies, was transferred to Pierre Fabre in July 2025 ¹. All regulatory activities, including BLA sponsorship, were transferred to Pierre Fabre in October 2025 ¹.

The company's existing cash, cash equivalents, and short-term investments of $8.482 million as of December 31, 2025, are not sufficient to fund planned operations for at least the next twelve months ¹. To secure additional capital, the company plans to pursue a combination of public or private security offerings, use of its ATM facility, issuance of debt, and/or execution of strategic transactions ¹. As of the date of the 10-K filing, the company's public float was less than $75 million, subjecting it to limitations under General Instruction I.B.6 to Form S-3, allowing sales of shares up to one-third of its public float under shelf registration statements in any twelve-month period ¹. Subsequent to December 31, 2025, the company sold an aggregate of 493,117 shares of common stock under the 2023 ATM Facility at an average price of $6.08 per share, for net proceeds of $3.0 million ¹.

The company faces substantial risks, including the possibility that its review of strategic alternatives may not result in a beneficial transaction, or could lead to a liquidation and dissolution of the business, potentially resulting in a total loss for stockholders ¹. The company has incurred substantial losses and requires significant near-term financing, with existing capital insufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern ¹. Failure to obtain necessary capital could force delays or termination of product development, manufacturing, or strategic alternative exploration ¹. The company's sole approved product, Ebvallo, is subject to annual re-assessment for its "exceptional circumstances" marketing authorization in the EU, UK, and Switzerland, and could be changed or suspended if post-marketing obligations are not met or the risk/benefit profile is deemed unacceptable ¹. The recent second Complete Response Letter from the FDA for the tab-cel BLA, claiming the ALLELE trial is no longer considered adequate due to deficiencies, poses a significant risk to U.S. approval and could lead to considerable delays or abandonment of the program ¹. Manufacturing risks include potential product loss due to contamination, equipment failure, or human error, as well as reliance on third-party suppliers and CMOs, which could lead to supply disruptions and increased costs ¹. The company's dependence on Pierre Fabre for worldwide development, manufacturing, and commercialization of tab-cel means any failure by Pierre Fabre to meet its obligations could adversely affect the business and the company's obligations under the HCRx Agreement ¹. Intellectual property protection is crucial, and the inability to obtain or maintain sufficient patent protection, or challenges to existing patents, could adversely affect commercialization and competitive positioning ¹. Product liability lawsuits, particularly given the inherent risks of testing product candidates in humans, could result in substantial liabilities exceeding insurance coverage ¹. The company is also exposed to risks from employee misconduct, noncompliance with regulatory standards, and cybersecurity threats, which could lead to significant liability, reputational harm, and operational disruptions ¹. Changes in tax laws or regulations, such as the immediate expensing of U.S. research and development expenditures under the One Big Beautiful Bill Act (OBBBA), or limitations on net operating loss carryforwards under Section 382 of the Internal Revenue Code, could adversely affect financial condition ¹.

Management's message to shareholders emphasizes a commitment to maximizing stockholder value through a process of exploring strategic alternatives, which commenced in January 2025 and includes potential acquisitions, mergers, asset sales, or licensing ¹. Despite having incurred substantial losses since inception, the company reported a net income of $32.7 million for the fiscal year ended December 31, 2025, attributed to commercialization revenue and significant reductions in operating expenses ¹. However, management explicitly states that existing cash, cash equivalents, and short-term investments of $8.482 million as of December 31, 2025, are insufficient to fund planned operations for at least the next twelve months, raising substantial doubt about the company's ability to continue as a going concern ¹. Strategic priorities include securing additional capital through various financing options, including public or private security offerings, debt, and strategic transactions, to alleviate the going concern risk ¹. Management also highlights the ongoing efforts with Pierre Fabre to address the FDA's concerns regarding the tab-cel BLA, following the second Complete Response Letter in January 2026, and anticipates providing a regulatory update in the second quarter of 2026 ¹.